Cancer cell growth and extracellular matrix remodeling mechanism of ascorbate; beneficial modulation by P. leucotomos

Anticancer Research

Volumn 29, Issue 8, 2009, Pages 3233-3238

  Philips, Neena ^a   Dulaj, Luiji ^a   Upadhya, Tajali ^a  

^a FAIRLEIGH DICKINSON UNIVERSITY   (United States)

Author keywords

Cancer; Matrix metalloproteinases; Polypodium leucotomos; Tissue inhibitor of matrix metalloproteinases; Transforming growth factor beta; Viability; Vitamin C

Indexed keywords

ASCORBIC ACID; CASPASE 3; HEAT SHOCK PROTEIN 20; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; INTERSTITIAL COLLAGENASE; POLYPODIUM LEUCOTOMOS EXTRACT; SMALL INTERFERING RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL GROWTH; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FERN; GROWTH INHIBITION; HUMAN; HUMAN CELL; MELANOMA CELL; POLYPODIUM; PRIORITY JOURNAL; RNA INTERFERENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIOXIDANTS; ASCORBIC ACID; CASPASE 3; CELL PROLIFERATION; CELLS, CULTURED; DRUG SYNERGISM; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; HEAT-SHOCK PROTEINS; HUMANS; MATRIX METALLOPROTEINASE 1; MELANOMA; PLANT EXTRACTS; POLYPODIUM; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 68549109511     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Westermarck J and Kahari VM: Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 12: 781-792, 1999. (Pubitemid 29220691)
2. Cox G and O'Byrne KJ: Matrix metalloproteinases and cancer. Anticancer Res 21: 4207-4220, 2001.
3. Merryman J I, Neilsen N and Staton DD: Transforming growth factor-beta enhances the ultraviolet-mediated stress response in p53-/- keratinocytes. Int J Oncol 13: 781-789, 1998. (Pubitemid 28435356)
4. Philips N and Onwubalili N: Anti-transforming growth factor-beta (TGF-β) increases the expressions of matrix metalloproteinase-1 (MMP-1) and growth factors in a renal adenocarcinoma cell line. Bios 73: 86-90, 2002.
5. Philips N and McFadden K: Inhibition of transforming growth factor-beta and matrix metalloproteinases by estrogen, and prolactin in breast cancer cells. Cancer Lett 206: 63-68, 2004. (Pubitemid 38281255)
6. Tsao CS: Inhibiting effect of ascorbic acid on the growth of human mammary tumor xenografts. Am J Clin Nutr 45: 1274S-12780S, 1991.
7. Liehr JG and Wheeler WJ: Inhibition of estrogen-induced renal carcinoma in Syrian hamsters by vitamin C. Cancer Res 43: 4638-4642, 1983.
8. Oliveira CP, Kassab P, Lopasso FP, Souza HP, Janiszewski M, Laurindo FR and Laudanna IK: Protective effect of ascorbic acid in experimental gastric cancer: reduction of oxidative stress. J World Gasteroenterol 9: 446-448, 2003. (Pubitemid 36372104)
9. Lutsenko E,Carcamo J and Golde D: Vitamin C prevents DNA mutation induced by oxidative stress. J Biol Chem 277: 27576, 2002.
10. Potdar, Kandarkar S and Sirsat S: Modulation by vitamin C of tumor incidence and inhibition in oral carcinogenesis. Funct Dev Morphol 3: 167-172, 1992.
11. Liu J, Nagao N, Kageyama K and Miwa N: Antimetastatic and anti-invasive ability of phospho-ascorbyl palmitated through intracellular ascorbate enrichment and the resultant antioxidant action. Oncol Res 11: 479-487, 1999.
12. Noto V, Henryk S, Taper S, Jiang YH, Jannsens J, Bonte J and De Loecker W: Effects of sodium ascorbate (vitamin C) and 2-methyl-1,4-naphthoquinone (vitamin K) treatment on humor tumor cell in vitro. I. Synergism of combined vitamin C and K action. Cancer 63: 901-909, 1989.
13. De Loecker W, Janssens J, Bonte J and Taper H: Effects of sodium ascorbate (vitamin C) and 2-methyl-1,4-naphthoquinone (vitamin K) treatment on human tumor cell growth in vivo. II. Synergism with combined chemotherapy action. Anticancer Res 13: 103-106, 1993.
14. Chen Q, Espey MG, Krishna MC, Mitchell J B, Corpe CP, Buettner GR, Shacter E and Levine M: Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. PNAS 102: 13604-13609, 2005. (Pubitemid 41420895)
15. Clement M, Ramalingam J, Long L and Halliwell B: The in vitro cytotoxicity of ascorbate depends on the culture medium used to perform the assay and involves hydrogen peroxide. Antioxid Redox Signal 3: 157-163, 2001. (Pubitemid 32241828)
16. Noto V, Henryk S, Taper S, Jiang Y H, Jannsens J, Bonte J and De Loecker W: Effects of sodium ascorbate (vitamin C) and 2-methyl-1,4-naphthoquinone (vitamin K) treatment on human tumor cell in vitro. I. Synergism of combined vitamin C and K action. Cancer 63: 901-906, 1989.
17. Agus D, Vera J and Golde D: Stromal cell oxidation. Cancer Res 59: 4555-4558, 1999.
18. Spielholz C, Golde DW, Houghton AN, Nualart F and Vera JC: Increased transport of dehydroascorbic acid without changes in sodium dependent ascorbate transport in human melanoma cells. Cancer Res 57: 2529-2537, 1997. (Pubitemid 27255917)
19. Philips N, Keller T and Holmes C: Reciprocal effects of ascorbate on cancer cell growth and the expression of matrix metalloproteinases and transforming growth factor-beta. Cancer Lett 256: 49-55, 2007. (Pubitemid 47337208)
20. Zhang H: P53 Plays a central role in UVA and UVB induced cell damage and apoptosis in melanoma cells. Cancer Lett 244: 229-238, 2005.
21. Calderwood SK: Chaperones and slow death - a recipe for tumor immunotherapy. Trends Biotechnol 57-59, 2005.
22. Philips N, Smith J, Keller T and Gonzalez S: Predominant effects of Polypodium leucotomos on membrane integrity, lipid peroxidation, and expression of elastin and matrixmetalloproteinase-1 in ultraviolet radiation-exposed fibroblasts, and keratinocytes. J Dermatol Sci 32: 1-9, 2003. (Pubitemid 36683041)
23. Gonzalez S, Alcaraz MV, Cuevas J, Perez M, Jaen P, Alvarex M and Villarrubia V: An extract of the fern polypodium leucotomos (Difur®) modulates Th1/Th2 cytokines balance in vitro and appears to exhibit anti-angiogenic activities in vivo: pathogenic relationships and therapeutic implications. Anticancer Res 20: 1567-1576, 2000. (Pubitemid 30628166)
24. Bernd A, Ramirez-Bosca A, Huber H, Diaz-Alperi H, Thaci D, Sewell A, Auintanilla-Almagro E and Holzmann H: In vitro studies on the immunomodulating effects of Poloypodium leucotomos extract on human leukocyte fractions. Arzneim-Forsch Drug Res 45: 901-904, 1995.
25. Mildner M, Ballaun C, Stichenwirth M, Bauer R, Gmeiner R, Buchberger M, Mlitz V and Tschachler E: Gene silencing in a human organic skin model. Biochem Biophys Res Commun 348: 76-82, 2006. (Pubitemid 44163484)
26. Lin SY, Lai WW, Chou CC, Kuo HM, Li TM, Chung GJ and Yang JH: Sodium ascorbate inhibits growth of the induction of cell cycle arrest and apoptosis in human malignant melanoma A375.S2 cells. Melanoma Res 509-519, 2006.
27. Verrax J, Cadrobbi J, Marques C, Taper H, Habraken Y, Piette J and Calderon PB: Ascorbate potentiates the cytotoxicity of menadione leading to an oxidative stress that kills cancer cells by a non-apoptotic caspase-3- independent form of cell death. Apoptosis 223-233, 2004. (Pubitemid 38987599)
28. Garrido C, Schmitt E, Cande C, Vahsen N, Parcellier A and Kroemer G: HSP27 and 70: Potential oncogenic apoptotic inhibitors. Cell Cycle 2: 579-584, 2003.
29. Neckers L: Heat-shock protein 90: the cancer chaperone. J Biosci 32: 517-530, 2007.
30. Trautinger F, Kindas-Mugge I, Dekrout B, Knobler RM, Metze D: Expression of the 27-kDa heat-shock protein in human epidermis and in epidermal neoplasms: an immunohistological study. Br J Dermatol 133: 194-202, 1995.
31. Eskenazi AE, Powers J, Pinkas J, Oesterreich S, Fuqua SA and Frantz CN: Induction of heat-shock protein 27 by hydroxyurea and its relationship to experimental metastasis. Clin Exp Metastasis 283-290, 1998. (Pubitemid 28201996)
32. Schmitt E, Maingret L, Puig PE, Rerole AL, Ghiringhelli F, Hammann A, Solary E, Kroemer G and Garrido C: Heat shock protein 70 neutralization exerts potent antitumor effects in animal models of colon cancer and melanoma. Cancer Res pp. 4191-4197, 2006.
33. Tsutsumi S and Neckers L: Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis. Cancer Sci 1536-1539, 2007. (Pubitemid 47308447)
34. Liotta LA and Stetler-Stevenson W: Metalloproteinases and malignant conversion: Does correlation imply casuality? J Natl Cancer Inst 81: 556-557, 1989.
35. Rundhaug JE: Matrix metalloproteinases, angiogenesis and cancer. Clinical Cancer Res 9: 551-554, 2003.
36. Noel A, Jost M and Maquoi E: Matrix metalloproteinases at cancer tumor-host interface. Semin Cell Dev Biol 1: 52-60, 2008. (Pubitemid 350235981)
37. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM and Shafie S: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284: 67-68, 1980. (Pubitemid 10098769)
38. Overall CM and Kleifeld O: Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nature Rev Cancer 6: 227-239, 2006.
39. Yuan J, Dutton MC and Scully SP: RNAi mediated MMP-1 silencing inhibits human chondrosarcome invasion. J Orthop Res 23: 1467-1474, 2005. (Pubitemid 41554684)
40. Jiang X, Dutton MC, Qi WN, Block J A, Garamszegi N and Scully SP: siRNA mediated inhibition of MMP-1 reduces invasive potential of a human chondrosoma cell line. J Cell Physiol 202: 723-730, 2005. (Pubitemid 40175848)
41. Kaminska B, Wesolowska A and Danilkiewicz M: TGF beta signaling and its role in tumor pathogenesis. Acta Biochem Pol pp. 329-337, 2005. (Pubitemid 41133768)